Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
| ▸ | EIF4E | P06730 | 2/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823724 | 0.85 | ALDH1A1 (0.63) | ALDH1A1HPGDKDM4EHPGDSNPC1 | |
| SCHEMBL5342686 | 0.83 | SMN1; SMN2 (0.60) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL28320566 | 0.83 | LDHA (0.61) | ALDH1A1EIF4EHPGDSGAA | |
| SCHEMBL3957201 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EMAPTTDP1 | |
| SCHEMBL2056680 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDIRAK4EIF4ECYP19A1 | |
| SCHEMBL1683639 | 0.82 | CNR2 (0.55) | ALDH1A1MAPTIRAK4NPC1RAB9A | |
| SCHEMBL12797778 | 0.82 | CYP19A1 (0.69) | ALDH1A1HPGDKDM4EMAPTEIF4E | |
| SCHEMBL3353616 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4EIRAK4HPGDSNPC1 | |
| SCHEMBL2056678 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAMAPTIRAK4 | |
| SCHEMBL9782130 | 0.79 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| CN-101370796-B | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-0262873-B1 | N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | ALDH1A1 810/4885HPGD 672/4885KDM4E 2714/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | ALDH1A1 865/4885HPGD 329/4885KDM4E 1709/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | ALDH1A1 810/4885HPGD 672/4885KDM4E 2714/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | ALDH1A1 810/4885HPGD 672/4885KDM4E 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.